Versartis, Inc. (VSAR) Files Form 4 Insider Selling : Joshua T Brumm Sells 1,448 Shares

Versartis, Inc. (VSAR): Joshua T Brumm , Chief Financial Officer of Versartis, Inc. sold 1,448 shares on Jun 15, 2016. The Insider selling transaction was reported by the company on Jun 17, 2016 to the Securities and Exchange Commission. The shares were sold at $10.63 per share for a total value of $15,392.24 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 17, 2016, Paul Westberg (Sr. VP, Business Development) sold 725 shares at $10.63 per share price.On May 20, 2016, Joshua T Brumm (Chief Financial Officer) sold 1,265 shares at $7.87 per share price.Also, On Nov 13, 2015, R Scott Greer (director) purchased 10,000 shares at $10.16 per share price.On Apr 16, 2015, Jeffrey L Cleland (President and CEO) sold 8,000 shares at $20.13 per share price.

Shares of Versartis Inc (VSAR) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.2 points or -1.84% at $10.67 with 79,177 shares getting traded. Post opening the session at $10.63, the shares hit an intraday low of $10.4501 and an intraday high of $11.21 and the price vacillated in this range throughout the day. The company has a market cap of $314 M and the number of outstanding shares has been calculated to be 2,94,28,913 shares. The 52-week high of Versartis Inc is $22.655 and the 52-week low is $6.17.

Versartis Inc Money Flow Index Chart

Versartis Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone VRS-317 for growth hormone deficiency (GHD) an orphan disease. The Company’s products include VRS-317 and XTEN Technology. VRS-317 combines the rhGH amino acid sequence utilized in rhGH products with a half-life extension technology XTEN to enable less frequent administration. The Company has initiated a Phase III clinical study of VRS-317 in pediatric growth hormone deficient patients. XTEN is a recombinant polypeptide that when genetically fused to a therapeutic payload of interest extends the in vivo half-life of these peptides and proteins in a tunable manner.

Leave a Reply

Versartis Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Versartis Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.